The estimated Net Worth of Patrick Johan Hendrik Stich... is at least $1.12 millió dollars as of 26 December 2019. Patrick Stich owns over 81,162 units of Applied Genetic Technologies Corp stock worth over $694,497 and over the last 5 years Patrick sold AGTC stock worth over $425,289.
Patrick has made over 2 trades of the Applied Genetic Technologies Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently Patrick sold 81,162 units of AGTC stock worth $425,289 on 26 December 2019.
The largest trade Patrick's ever made was selling 81,162 units of Applied Genetic Technologies Corp stock on 26 December 2019 worth over $425,289. On average, Patrick trades about 41,853 units every 19 days since 2019. As of 26 December 2019 Patrick still owns at least 1,780,762 units of Applied Genetic Technologies Corp stock.
You can see the complete history of Patrick Stich stock trades at the bottom of the page.
Over the last 11 years, insiders at Applied Genetic Technologies Corp have traded over $12,578,298 worth of Applied Genetic Technologies Corp stock and bought 760,946 units worth $8,946,827 . The most active insiders traders include Plc Gsk, Edward Hurwitz és Ventures, Inc. Med Immune. On average, Applied Genetic Technologies Corp executives and independent directors trade stock every 89 days with the average trade being worth of $18,318. The most recent stock trade was executed by Stephen W Potter on 30 June 2022, trading 8,070 units of AGTC stock currently worth $6,214.
Applied Genetic Technologies Corp. (AGTC) is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC's most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company's industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding.
Applied Genetic Technologies Corp executives and other stock owners filed with the SEC include: